##  [Filing of IND Submissions and Amendments with Zero Errors](/case-studies/filing-of-ind-submissions-and-amendments-with-zero-errors) 

- [Medicinal Products](/case-studies-main-categories/medicinal-products)
- [Publishing and Submission](/case-studies-main-categories/publishing-and-submission)





[US FDA](/case-studies-heath-authority/us-fda)

 

 ![Filing of IND Submissions and Amendments with Zero Errors]()

A top US-based life sciences consulting firm sought Regulatory assistance from Freyr for filing Investigational New Drug (IND) submissions and amendments with the USFDA.

Freyr successfully completed the end-to-end publishing activities for the project within a tight timeline. With granular document-level publishing (DLP) services, the IND submissions and document amendments were made on time without any errors or warnings from the USFDA.

Discover how Freyr provided comprehensive Regulatory services and made high-quality submissions on schedule using Agency-recommended tools. Download the case study for more details.



Fill the form below to download the Case Study

 You must have JavaScript enabled to use this form.

  

  

  

 How did you hear about us?Search EngineE-mail CampaignGoogle AdsSocial MediaLink from another websiteColleague’s RecommendationNewsletterPrinted BrochureOther 

  

 

 

     I have read the [privacy policy](https://www.freyrsolutions.com/privacy-policy) 



 

 Submitted Page URL  

 Website URL  

 Content Type  

 Form Name